Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 24, 2026

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse

View original at globenewswire.com
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes at…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dupixent has been approved in Japan as the first targeted medication for treatment of adults with bullous pemphigoid

    60% confidence

  • Dupilumab has been studied in more than 60 clinical studies involving more than 12,000 patients with various chronic diseases partly due to type 2 inflammation

    60% confidence

  • Dupixent is a fully human monoclonal antibody that inhibits IL-4 and IL-13 pathway signaling and is not an immunosuppressant

    60% confidence

  • More than four times as many patients treated with Dupixent achieved sustained disease remission compared to placebo (18% vs. 4%; p=0.0250) at week 36

    60% confidence

  • More than 1.4 million patients are treated with Dupixent worldwide

    60% confidence

  • Dupixent has received regulatory authorizations in more than 60 countries for one or more indications

    60% confidence

  • Bullous pemphigoid is the seventh approved indication for Dupixent in Japan

    60% confidence

  • Treatment-related adverse events occurred in 26% of patients treated with Dupixent and in 15% of patients on placebo, with conjunctivitis being the most frequently reported at 4%

    60% confidence

  • Dupixent's development program has shown significant clinical benefit and reduction in type 2 inflammation in phase 3 studies, establishing that IL-4 and IL-13 are two key and central factors of type 2 inflammation

    60% confidence

Cited in these Via News reports